Data at heart rhythm 2023 highlight key boston scientific therapies

Additional real-world outcomes further demonstrate safety, efficacy and procedural reproducibility of the farapulse™ pulsed field ablation system* results from global trial of the polarx™ cryoablation system* meet safety and effectiveness endpoints marlborough, mass. , may 20, 2023 /prnewswire/ -- boston scientific corporation (nyse: bsx) today announced data supporting use of the company's key electrophysiology and cardiac rhythm management therapies, and the watchman flx™ left atrial appendage closure (laac) device.
BSX Ratings Summary
BSX Quant Ranking